Association Between Size Of Residual Non-Functioning Pituitary Adenoma and Regrowth after Surgery
Keywords:
pituitary adenoma, non-functioning pituitary adenoma, residual non-functioning pituitary adenomaAbstract
Objective: A residual non-functioning pituitary adenoma (NFPA) after surgical removal is a well-known predictive risk factor for the regrowth of tumors, but there is no guide for the size of the residual tumor to predict. This study utilized the size of the residual tumor to predict the regrowth of non-functioning pituitary adenoma after surgical removal and investigated other predictors for tumor regrowth.
Methods: The retrospective study included 123 newly diagnosed NFPA cases that had been operated on at Maharaj Nakorn Chiang Mai Hospital from January 2009 to December 2020. The size of the residual tumor was monitored through CT scans or 1.5 Tesla MRI interpreted by a neurosurgeon and neuroradiologists. Multivariate analysis was employed to identify predictors of tumor regrowth, and the Kaplan-Meir method was used to determine regrowth-free survival.
Results: This study comprised 123 patients newly diagnosed with NFPA after surgical removal. Comparisons were made between a regrowth/recurrence tumor group (22 patients) and a no-progression group (101 patients). Univariate analysis indicated that residual tumor size, especially tumors larger than 1 cm (HR 4.00, 95%CI 1.16-13.83, p = 0.03), was the most significant factor. In multivariate analysis, adjusted for radiotherapy, hormonal deficit, age, and gender, it was revealed that regrowth or recurrence of the tumor depends on the size, especially more than 1 cm (HR 6.52, 95%CI 1.37-31.07, p = 0.02).
Conclusion: Residual non-functioning pituitary adenoma after surgical removal could predict progression in the future, particularly for sizes larger than 1 cm. Neurosurgeons must pay attention to patients in this group.
Downloads
References
Chen Y, Wang CD, Su ZP, Chen YX, Cai L, Zhuge QC, et al. Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and metaanalysis. Neuroendocrinology. 2012;96(4):333-42.
Hayhurst C, Taylor PN, Lansdown AJ, Palaniappan N, Rees DA, Davies JS. Current perspectives on recurrent pituitary adenoma: the role and timing of surgery vs adjuvant treatment. Clinical endocrinology. 2020;92(2):89-97.
Chai HR, Dae SY, Young JP, Won SY, Jung AL, Chul YK . Radiotherapy for pituitary adenomas: longterm outcome and complications. Radiat Oncol J. 2011;29(3):156-63.
Jelena M, Asmaa D, Dongyun Z, Abdul Z, Marvin B, Marilene BW, et al. Residual tumor confers a 10-fold increased risk of regrowth in clinically nonfunctioning pituitary tumors. J Endocr Soc. 2019 Jul 23;3(10):1931-41.
Sophie B, Françoise G, Michèle K, Fabrice P, Stephan G, Christian R, et al. Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol. 2010 Aug;163(2):193-200.
Jee SK, Youn SL, Min JJ, Yong KH. The predictive value of pathologic features in pituitary adenoma and correlation with pituitary adenoma recurrence. J Pathol Transl Med. 2016;50:419-25.
Georg W, Stefan W, Matthias P, Ingeborg F, Adelheid W, Joerg W, et al. Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. J Neurosurg. 2009;111:563-71.
Roger G, Brooke S, Tessa HW. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol. 2008;39:758–66.
Shehan J, Lee CC, Bodach ME, Tumialan LM, Oyesiku LM, Patil CG, et al. Congress of Neurological Surgeons systematic review and evidence-based guideline for the management of patients with residual or recurrent nonfunctioning pituitary adenomas. Congress of Neurological Surgeons. 2016. Neurosurgery. 2016 Oct;79(4):E539-40. doi:10.1227/NEU.0000000000001385.
Marco L, Pietro M, Raffaella B, Paolo R, Maria RT, Stefania BM, et al. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg. 2008;108:525–32.
Seejore K, Alavi SA, Pearson SM, Robins JMW ,Alromhain B, Sheikh A, et al. Post-operative volumes following endoscopic surgery for non-functioning pituitary macroadenomas are predictive of further intervention, but not endocrine outcomes. BMC Endocr Disord. 2021;21:116. https://doi:10.1186/s12902-021-00777-8.
Matoušek P, Buzrla P, Reguli Š, KrajIa J, DvoláIková J, Lipina R, et al. Factors that predict the growth of residual nonfunctional pituitary adenomas: correlations between relapse and cell cycle markers. Biomed Res Int. 2018;4:1-9.
Osamura RY, Lopes MBS, Grossman A, Matsuno A, Korbonits M, Trouillas J, et al. Tumours of the pituitary gland. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO classification of tumours of endocrine organs. 4th ed. Lyon: IARC Publications; 2017. p11-63.
Yao X, Gao H, Li C, Wu L, Bai J, Wang J, et al. Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas. J Neuro-Oncol. 2017;132(2):199–206.
Sadeghipour A, Mahouzi L, Salem MM, EbrahimNejad S, Asadi-Lari M, Radfar A, et al. Ki67 labeling correlated with invasion but not with recurrence. Appl Immunohistochem Mol Morphol. 2017 May/ Jun;25(5):341-5.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles in this journal are copyrighted by the x may be read and used for academic purposes, such as teaching, research, or citation, with proper credit given to the author and the journal.use or modification of the articles is prohibited without permission.
statements expressed in the articles are solely the opinions of the authors.
authors are fully responsible for the content and accuracy of their articles.
other reuse or republication requires permission from the journal."
